EMPOWER Study: Using a Chatbot for Breast Cancer Screening Follow-up
This study, called EMPOWER, is looking at how a digital tool called a chatbot can help women with their breast cancer screening. The chatbot will be used after you have a mammogram (an X-ray of the breast) to answer questions and provide information. We want to see if using this chatbot helps women stick to their recommended screening schedule. You can join if you are an adult woman (18 or older), speak English or Spanish, and are having a routine mammogram at the University of Utah. The study will compare women who receive usual care to those who also use the chatbot. We are hoping to enroll 2700 participants.
- Study design
- This study is interventional and will involve 2700 participants. You will be randomly assigned to either receive usual care or usual care plus the chatbot.
- What's involved
- You will complete a baseline survey at the start of the study. The chatbot communication will be initiated through your preferred contact method (text or email) and can be completed via phone or website.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your screening adherence will be measured for up to 24 months after you start the study intervention.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Screening Adherenceup to 24 months from initiation of study intervention
This outcome measure will test the addition of virtual navigation to usual processes of care to increase screening adherence for underserved women undergoing mobile mammography who have an abnormal breast cancer screening exam. Screening adherence will be measured as a two-point survey item (Yes/No). This outcome measure will report the proportion of participants who self-reported screening adherence.